Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Cerebrus uses studies on Redux to design new antiobesity agents

Nov. 10, 1997

Profile of Green Cross's rHSA

Nov. 7, 1997

Cell Genesys reports delivery of erythropoietin gene therapy

Nov. 7, 1997

Neuropeptide Y5 receptor emerges as an important new target in obesity

Nov. 6, 1997

NPS and SmithKline Beecham extend osteoporosis agreement

Nov. 5, 1997

Labeling changes for Rezulin; FDA and manufacturer recommend liver function tests

Nov. 5, 1997

Novo Nordisk reports improved human insulin derivatives

Nov. 5, 1997

Phase III safety and efficacy data reported for one-alpha D2

Nov. 4, 1997

Preclinical results with Ergo Science's neuroendocrine resetting therapy

Nov. 4, 1997

Sequana and Glaxo Wellcome revise diabetes/obesity alliance

Nov. 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...